Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Mitral transcatheter edge-to-edge repair in patients with severe pulmonary hypertension

Shechter A, Gupta A, Kaewkes D, Taheri H, Nagasaka T, Patel V, Suruga K, Koseki K, Koren O, Makar M, Skaf S, Patel D, Chakravarty[...]

Utility and utilization of transabdominal ultrasound in pediatric patients with acute recurrent or chronic pancreatitis

Norris N, Troendle D, Wilschanski M, Wang F, Cress GA, Abu-El-Haija MA, Chugh A, Cohen RZ, Downs EM, Fishman DS, Gariepy CE, Giefer MJ, Gonska[...]

Current State of Artificial Intelligence in Assessing Cardiac Function

Yuan V, Lee K, Ambrosy AP, Ouyang D, Ieki H. Current State of Artificial Intelligence in Assessing Cardiac Function. Curr Cardiol Rep. 2025 Nov 27;27(1):158.[...]